New CDDO Arylboronate Ester Derivatives with High Selectivity and Low Toxicity

Area of Science:

• Medicinal Chemistry
• Organic Chemistry
• Cancer Biology

Background:

• Oleanolic acid derivatives, like CDDO-Me, often lack tumor selectivity.
• Cancer cells exhibit elevated levels of reactive oxygen species (ROS).

Purpose of the Study:

• To design and synthesize novel CDDO arylboronate ester derivatives with improved cancer cell selectivity.
• To evaluate the efficacy and safety of compound 4, a promising CDDO derivative.

Main Methods:

• Synthesis of 17 new CDDO arylboronate ester derivatives.
• In vitro antiproliferation assays using BGC-823 cancer cells.
• In vivo pharmacokinetic and tumor inhibition studies in ICR mice.

Main Results:

• Compound 4 showed the highest selectivity for cancer cells among the tested derivatives.
• ROS transformed compound 4 to 4H, enhancing covalent binding and antiproliferation (IC50: 0.37 μM vs 2.11 μM).
• Compound 4 induced apoptosis in BGC-823 cells by increasing ROS levels, with a higher LD50 (91.2 mg/kg) and tumor inhibition rate (86.2%) than CDDO-Me.

Conclusions:

• Compound 4 represents an effective modification of CDDO, significantly increasing cancer cell selectivity.
• The ROS-triggered transformation of 4 to 4H is a key mechanism for its enhanced anti-cancer activity.
• This strategy offers a promising approach for developing more targeted cancer therapeutics.